Cavendish Financial PLC AGM Trading Statement (0410O)

TIDMCAV

RNS Number : 0410O

Cavendish Financial PLC

29 September 2023

29 September 2023

For immediate Release

Cavendish Financial plc ("Cavendish" or the "Group")

AGM Trading Statement

Cavendish Financial plc announces the following update ahead of its Annual General Meeting to be held today at 10.00 am:

On 8 September, finnCap Group plc and Cenkos Securities plc completed their merger to create Cavendish Financial plc, a full-service investment bank for ambitious growth companies.

The combined operation consists of just under 200 people operating from its headquarters in One Bartholomew Close, London and its Scottish office in Edinburgh. With 220 quoted clients, the Group has the largest retained client base amongst UK small and midcap investment banks, making it the go-to financial advisory firm for growth and investment companies. In addition to equity capital markets, Cavendish has expertise in M&A, debt advisory and private growth capital. The Group also has a strong global reach through its membership of Oaklins, an international advisory network.

Since the merger, the Group has relocated all of the London based Cenkos team to its London headquarters, launched the new operating brand Cavendish, centralised trading onto a single platform and made substantial progress with its IT integration. The integration of the operations team, a key part of delivering the synergies is also nearing completion. The Group will provide a further update on synergy realisation within its inaugural interim results expected to be announced in December.

Trading across the City has been quiet during the Summer, but since merger completion the Group has already announced a number of significant transactions which will close in the coming months including acting as sole adviser to Round Hill Royalty Fund Limited on its offer from Concord Cadence Limited, fundraisings for Haydale Graphene PLC and Shield Therapeutics plc and obtaining key regulatory clearances for the equity financing of Allergy Therapeutics by ZQ Capital and Southern Fox.

Contacts:

Cavendish Financial plc Tel: [phone]

John Farrugia, co-CEO

Julian Morse, co-CEO

Grant Thorton UK LLP (Nominated Adviser to Cavendish) Tel: [phone]

Philip Secrett/Samantha Harrison/Samuel Littler

Hudson Sandler (PR adviser to Cavendish)

Dan de Belder

Tel: [phone]

Rebekah Chapman

Tel: [phone]

About Cavendish

Cavendish is a UK champion for ambitious growth and investment companies. The Group is trusted by public and private companies, operating across industry sectors, to deliver expert services in equity capital markets, M&A, debt advisory and growth capital.

Cavendish has offices in the City of London and Edinburgh and has a global reach through its membership of Oaklins. Cavendish Financial plc is quoted on AIM.

For more information on Cavendish, please visit www.cavendish.com

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGMUWROROUUKUAR

(END) Dow Jones Newswires

September 29, 2023 02:00 ET (06:00 GMT)